Fetuin-A as a risk factor for arteriovenous fistula failure in chronic kidney disease patients with hemodialysis through vascular calcification mechanism: Systematic review and meta-analysis
Restricted accessReview articleFirst published online 2026
Fetuin-A as a risk factor for arteriovenous fistula failure in chronic kidney disease patients with hemodialysis through vascular calcification mechanism: Systematic review and meta-analysis
Arteriovenous Fistula (AVF) failure remains a significant challenge in patients on hemodialysis. No meta-analysis has concluded the relationship between fetuin-A serum levels, arterial calcification, and AVF failure. This study aims to evaluate the relationship between fetuin-A levels and AVF failure through vascular calcification in CKD patients undergoing hemodialysis. This meta-analysis was conducted according to the PRISMA guideline. On October 1st, 2024, a literature search was conducted in PubMed and ScienceDirect. Data were analyzed using Review Manager for pooled hazard ratio and standardized mean difference (SMD), while MedCalc software was used to calculate the pooled correlation coefficient. A total of 26 observational studies were included. Meta-analysis showed that fetuin-A levels were negatively correlated with vascular calcification (r = −0.530; 95% CI: −0.781 to −0.132; p = 0.011). The mean fetuin-A levels were lower in the group with vascular calcification than those without calcification (SMD = −1.71; 95% CI: −2.58 to −0.85; p = 0.0001). Patients with vascular calcification had a 2.98 times higher risk of AVF failure (OR = 2.98; 95% CI: 1.78–4.99; p < 0.0001). Three studies showed that high fetuin-A levels were a protective factor against AVF failure (HR = 0.76; 95% CI: 0.63–0.91; p = 0.003). Low fetuin-A levels were associated with increased vascular calcification and risk of AVF failure in CKD patients undergoing hemodialysis. These findings suggest the potential of fetuin-A as a predictive biomarker and therapeutic target in reducing AVF failure. Further studies with standard testing methods are recommended to confirm this association.
ChenTKKnicelyDHGramsME.Chronic kidney disease diagnosis and management: a review. JAMA2019; 322(13): 1294–1304.
2.
Garcia-LopezAESánchezRVesgaJI, et al. Factors associated with hemodialysis vascular access failure: a retrospective study in Colombia. Rev Colomb Nefrol2023; 10(1): 1–14.
3.
JankovicADamjanovicTDjuricZ, et al. Calcification in arteriovenous fistula blood vessels may predict arteriovenous fistula failure: a 5-year follow-up study. Int Urol Nephrol2017; 49(5): 881–887.
4.
LyuBBanerjeeTSciallaJJ, et al. Vascular calcification markers and hemodialysis vascular access complications. Am J Nephrol2018; 48(5): 330–338.
5.
RudloffSJahnen-DechentWHuynh-DoU.Tissue chaperoning-the expanded functions of fetuin-A beyond inhibition of systemic calcification. Pflugers Arch2022; 474(8): 949–962.
6.
IxJHKatzRde BoerIH, et al. Fetuin-A is inversely associated with coronary artery calcification in community-living persons: the Multi-Ethnic Study of Atherosclerosis. Clin Chem2012; 58(5): 887–895.
7.
JungHHBaekHJKimSW.Fetuin-A, coronary artery calcification and outcome in maintenance hemodialysis patients. Clin Nephrol2011; 75(5): 391–396.
8.
PateinakisPPapagianniADoumaS, et al. Associations of fetuin-A and osteoprotegerin with arterial stiffness and early atherosclerosis in chronic hemodialysis patients. BMC Nephrol2013; 14: 122.
9.
ZhengSde Las FuentesLBierhalsA, et al. Relation of serum fetuin-A levels to coronary artery calcium in African-American patients on chronic hemodialysis. Am J Cardiol2009; 103(1): 46–49.
10.
TurkmenKGorguluNUysalM, et al. Fetuin-A, inflammation, and coronary artery calcification in hemodialysis patients. Indian J Nephrol2011; 21(2): 90–94.
11.
KirkpanturAAltunBHazirolanT, et al. Association among serum fetuin-A level, coronary artery calcification, and bone mineral densitometry in maintenance hemodialysis patients. Artif Organs2009; 33(10): 844–854.
12.
El-ShehabyAMZakariaAEl-KhatibM, et al. Association of fetuin-A and cardiac calcification and inflammation levels in hemodialysis patients. Scand J Clin Lab Invest2010; 70(8): 575–582.
13.
JanszTTvan ReekumFEÖzyilmazA, et al. Coronary artery calcification in hemodialysis and peritoneal dialysis. Am J Nephrol2018; 48(5): 369–377.
14.
FitzpatrickJKimEDSozioSM, et al. Calcification biomarkers, subclinical vascular disease, and mortality among multiethnic dialysis patients. Kidney Int Rep2020; 5(10): 1729–1737.
15.
KuźniarJPorazkoTKlingerM.Relationship between fetuin-A concentration, elevated levels of inflammatory markers, and arterial wall stiffness in end-stage kidney disease. J Ren Nutr2008; 18(1): 83–86.
16.
CoenGManniMAgnoliA, et al. Cardiac calcifications: fetuin-A and other risk factors in hemodialysis patients. ASAIO J2006; 52(2): 150–156.
17.
KimHIAnWS.Comparison of fetuin-A, vitamin D, monounsaturated fatty acid, and vascular calcification on plain radiography between dialysis modalities. Iran J Kidney Dis2013; 7(6): 453–460.
18.
MutluayRKonca DeğertekinCIşıktaş SayılarE, et al. Serum fetuin-A is associated with the components of MIAC(malnutrition, inflammation, atherosclerosis, calcification) syndrome in different stages of chronic kidney disease. Turk J Med Sci2019; 49(1): 327–335.
19.
LokCEHuberTSLeeT, et al. KDOQI clinical practice guideline for vascular access: 2019 update. Am J Kidney Dis2020; 75(4 Suppl 2): S1–S164.
20.
WangDChuXCaoJ, et al. Correlation of serum Klotho, fetuin-A, and MGP levels with coronary artery calcification in maintenance hemodialysis patients. Clinics (Sao Paulo)2024; 79: 100417.
21.
TalibANakagawaNSaitoE, et al. The balance of fetuin-A and osteoprotegerin is independently associated with diastolic dysfunction in hemodialysis patients. Hypertens Res2012; 35(4): 426–433.
22.
CozzolinoMGalassiABiondiML, et al. Serum fetuin-A levels link inflammation and cardiovascular calcification in hemodialysis patients. Am J Nephrol2006; 26(5): 423–429.
23.
LeeCTChuaSHsuCY, et al. Biomarkers associated with vascular and valvular calcification in chronic hemodialysis patients. Dis Markers2013; 34(4): 229–235.
24.
MuzastiRALoesnihariR.High fetuin-A level as a protective factor to abdominal aortic calcification in Indonesian regular hemodialysis patients. Open Access Maced J Med Sci2019; 7(5): 721–725.
25.
KimHRKimSHHanMJ, et al. The ratio of osteoprotegerin to fetuin-a is independently associated with vascular stiffness in hemodialysis patients. Nephron Clin Pract2013; 123(3–4): 165–172.
26.
ChoiSJYoonHEKimYS, et al. Pre-existing arterial micro-calcification predicts primary unassisted arteriovenous fistula failure in incident hemodialysis patients. Semin Dial2015; 28(6): 665–669.
27.
Joseph LoZTayWMLeeQ, et al. Predictors of radio-cephalic arteriovenous fistulae patency in an Asian population. J Vasc Access2016; 17(5): 411–416.
28.
Roca-TeyRBordesRMartínez-CercósR, et al. The impact of pre-existing radial artery pathology by histological assessment on the maturation, function and patency of the radiocephalic fistula for hemodialysis. Int Angiol2019; 38(3): 239–249.
29.
StolicRVTrajkovicGZPericVM, et al. The influence of atherosclerosis and plasma D-dimer concentration in patients with a functioning arteriovenous fistula for maintenance hemodialysis. Int Urol Nephrol2008; 40(2): 503–508.
30.
GeorgiadisGSGeorgakarakosEIAntoniouGA, et al. Correlation of pre-existing radial artery macrocalcifications with late patency of primary radiocephalic fistulas in diabetic hemodialysis patients. J Vasc Surg2014; 60(2): 462–470.
31.
Roca-TeyRRamírezdeArellanoMGonzález-OlivaJC, et al. Is fetuin-A a biomarker of dialysis access dysfunction?J Vasc Access2023; 24(3): 458–464.
32.
ChenHYChiuYLChuangYF, et al. Association of low serum fetuin A levels with poor arteriovenous access patency in patients undergoing maintenance hemodialysis. Am J Kidney Dis2010; 56(4): 720–727.
33.
OcakGRotmansJIVossenCY, et al. Type of arteriovenous vascular access and association with patency and mortality. BMC Nephrol2013; 14: 79.
34.
WestenfeldRSchäferCKrügerT, et al. Fetuin-A protects against atherosclerotic calcification in CKD. J Am Soc Nephrol2009; 20(6): 1264–1274.
35.
HouYCLuCLLuKC.Mineral bone disorders in chronic kidney disease. Nephrology (Carlton)2018; 23 Suppl4: 88–94.
36.
HoltSGSmithER.Fetuin-A-containing calciprotein particles in mineral trafficking and vascular disease. Nephrol Dial Transplant2016; 31(10): 1583–1587.
37.
UedonoHMoriKOchiA, et al. Effects of fetuin-A-containing calciprotein particles on posttranslational modifications of fetuin-A in HepG2 cells. Sci Rep2021; 11(1): 7486.
38.
MukhopadhyaySMondalSAKumarM, et al. Proinflammatory and antiinflammatory attributes of fetuin-a: a novel hepatokine modulating cardiovascular and glycemic outcomes in metabolic syndrome. Endocr Pract2014; 20(12): 1345–1351.
39.
WangHSamaAE.Anti-inflammatory role of fetuin-A in injury and infection. Curr Mol Med2012; 12(5): 625–633.
40.
Chekol AbebeETilahun MucheZBehaileTMariamA, et al. The structure, biosynthesis, and biological roles of fetuin-A: a review. Front Cell Dev Biol2022; 10: 945287.
41.
AllonMLitovskySYoungCJ, et al. Correlation of pre-existing vascular pathology with arteriovenous graft outcomes in hemodialysis patients. Am J Kidney Dis2013; 62(6): 1122–1129.
42.
WangNAngioiAHansetN, et al. Individualizing the lifesaving journey for calciphylaxis: addressing rapidly progressive attacks with multidimensional and AI research for regenerative medicine. Ren Fail2024; 46(2): 2392846.
43.
VoTMDisthabanchongS.Are there ways to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease?World J Cardiol2014; 6(5): 216–226.
44.
CiancioloGCapelliIAngeliniML, et al. Importance of vascular calcification in kidney transplant recipients. Am J Nephrol2014; 39(5): 418–426.
45.
GriesJJSakamotoTChenB, et al. Revascularization strategies for acute and chronic mesenteric ischemia: a narrative review. J Clin Med2024; 13(5): 1217.
46.
LareyreFAugèneEMassalouD, et al. Vascular calcifications are associated with increased mortality in patients with acute mesenteric ischemia. Ann Vasc Surg2021; 72: 88–97.
